Center for Precision Medicine for High-risk Pediatric Cancer Publications

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

9 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Precision medicine efforts across oncology resulted in 33 high-impact (impact factor >10) publications in the past year alone (i.e., 2021-22). Here are some highlights of our published research.

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Lancet Oncol · April, 2022
Decade-long leukemia remissions with persistence of CD4+ CAR T-cells
Nature · February, 2022
Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib
Cancer Genet · January, 2022
Single-cell multiomics reveals increased plasticity, resistant populations and stem-cell-like blasts in KMT2A-rearranged leukemiaSingle-cell multiomics reveals increased plasticity, resistant populations and stem-cell-like blasts in KMT2A-rearranged leuke
Blood · December, 2021
Network analysis reveals synergistic genetic dependencies for rational combination therapy in Philadelphia chromosome-like acute lymphoblastic leukemia
Clin Cancer Res · September, 2021
Integrative bulk and single-cell profiling of pre-manufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy
Cancer Discov · April, 2021
Opportunities and Challenges in Drug Development for Pediatric Cancers
Cancer Discov · March, 2021
Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers
Science Advances · July, 2020
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Lancet Oncol · May, 2018
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
N Engl J Med · February, 2018